Overall, these findings unravelled that, in the cohort of patients expressing wild-type FGFR2 protein, only a subgroup (19.0%) of cases showed a concomitant activation of FGFR2 signalling in the tumor tissue; in the remaining cases, despite the expression of the receptor, the downstream signalling cascade resulted inactivated. The gene discussed is FGFR2; the disease is neoplasm.